As men and women around the world seek better medical options to address infertility, Igyxos Biotherapeutics is dedicated to answering their call. We’re harnessing breakthrough science in monoclonal antibodies to pioneer novel therapeutics that aim to transform the treatment of infertility.
We’re singularly focused on improving reproductive health outcomes for men and women struggling with infertility.
Igyxos’ unique scientific approach overcomes the limitations of current infertility treatments by identifying powerful monoclonal antibodies that boost the activity of Follicle Stimulating Hormone (FSH) in reproduction.
Our first clinical candidate, IGX12, has a compelling body of preclinical data that underlies its significant potential for increasing the efficacy and potency of FSH.
At Igyxos, we are forerunners of change. Harnessing decades of experience in reproductive health, we aim to transform the effectiveness, efficiency, and economics of infertility treatment.
Igyxos selected for the French Tech 120 (FT120) program for the third consecutive year
Igyxos is pleased to announce that it has been selected for the third consecutive year for the French Tech 120 (FT120) program. The objective of the FT120 is to support the development of these new technological players that respond to the major challenges facing society. The selection, based on financial criteria of fundraising or hypergrowth of sales, is open to all models of startups (digital, deeptech, industrial) and all sectors of activity.
Global patient need for new medical options for infertilty
Infertility is a disease of the male or female reproductive system that is estimated to affect 48 million couples and 186 million individuals globally, according to the World Health Organization.